Intravenous glyburide treatment may reduce dangerous brain swelling after stroke

August 23, 2016

A phase 2 clinical trial of a drug that may alleviate brain swelling -- a dangerous stroke complication -- suggests the treatment may help reduce brain injury and death, and information from the study will help design the phase 3 trial. While the trial did not meet its prespecified primary objective, as described in a paper receiving online release in The Lancet Neurology, it did provide additional evidence that intravenous glyburide treatment may improve patient outcomes.

"Although a follow-up clinical study is needed to confirm our preliminary finding, this is the first time a drug has been tested to prevent brain swelling after a major stroke," says W. Taylor Kimberly, MD, PhD, of the Massachusetts General Hospital (MGH) Department of Neurology, co-corresponding author of the report. "We believe that glyburide treatment may be an important strategy to minimize injury resulting from brain swelling."

Strokes caused by blockage of the blood supply to a large area of the brain can lead to the accumulation of fluids called edema, causing brain tissue to swell. Since the brain is confined with the skull, significant swelling and the resulting increased pressure can push brain structures out of their normal position, leading to a 50 percent mortality rate for this complication. Treatment with drugs designed to draw fluids out of the brain have had limited effectiveness, and hemicraniectomy -- surgical removal of a portion of the skull to allow brain tissue to swell freely -- is not appropriate for all patients and carries its own risk of complications.

Previous studies in animal models of stroke have suggested that glyburide -- a drug used to treat type 2 diabetes - might prevent brain swelling in stroke patients. A pilot study led by Kimberly and his co-corresponding author Kevin Sheth, MD, Department of Neurology, Yale University School of Medicine, indicated that glyburide treatment was safe for stroke patients and led to the phase 2 trial, sponsored by Remedy Pharmaceuticals. Conducted at 18 hospitals across the U.S., the study - entitled the Glyburide Advantage in Malignant Edema and Stoke (GAMES-RP) trial -- enrolled 77 patients with strokes affecting one-third or more of a brain hemisphere. Participants were randomly assigned to continuous intravenous treatment with either glyburide or a placebo for a total of 72 hours.

The prespecified primary endpoint of the study was the proportion of patients who, 90 days after their stroke, achieved scores of 0 to 4 on a standardized stroke scale -- a range extending from no symptoms to moderately severe disability - without surgery to relieve brain swelling. While around 40 percent of those in each group met those criteria, the authors note that the decision to have surgery was made by the physicians caring for each patient and may have been arrived at more often at some sites than at others.

"Deciding to proceed to a hemicraniectomy is complicated and depends on the judgment of the stroke neurologist, of the neurosurgeon, and the wishes of patients or their families," says Sheth. "This led to variation in practice across the sites, which is appropriate for clinical care but not ideal for the endpoint of a clinical trial; and we believe this is the main reason the primary endpoint was not reached."

The results for other endpoints, however, were more promising - particularly the brain imaging measure of midline shift, which reflects the extent to which brain structures are pressed out of place by brain swelling. "The degree of midline shift was reduced about 40 percent in patients treated with glyburide, and there was a similar reduction in levels of MMP-9, a biomarker that previous studies have associated with brain swelling after stroke," says Kimberly. "From a clinical standpoint, there was a 50 percent reduction in mortality and a promising trend towards better functional outcome at 90 days." The results of this study are being used to design the phase 3 trial, which will begin enrolling patients in 2017.
Along with Kimberly, an assistant professor of Neurology at Harvard Medical School, and Sheth, an associate professor of Neurology and of Neurosurgery at Yale University School of Medicine, co-authors of the Lancet Neurology paper are Ann Christin Ostwaldt, PhD, MGH Neurology; Lauren Beslow, MD, Yale Neurology and Pediatrics; Jordan Elm, PhD, Medical University of South Carolina; Bradley Molyneaux, MD, University of Pittsburgh; Holly Hinson, MD, Oregon Health Sciences University; Gordon Sze, MD, Yale Radiology; Gregory del Zoppo, MD, University of Washington; Marc Simard, MD, University of Maryland; and Sven Jacobson, Remedy Pharmaceuticals.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School.

The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $800 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals, earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2016 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America's Best Hospitals."

Massachusetts General Hospital

Related Stroke Articles from Brightsurf:

Stroke alarm clock may streamline and accelerate time-sensitive acute stroke care
An interactive, digital alarm clock may speed emergency stroke care, starting at hospital arrival and through each step of the time-sensitive treatment process.

Stroke patients with COVID-19 have increased inflammation, stroke severity and death
Stroke patients who also have COVID-19 showed increased systemic inflammation, a more serious stroke severity and a much higher rate of death, compared to stroke patients who did not have COVID-19, according a retrospective, observational, cross-sectional study of 60 ischemic stroke patients admitted to UAB Hospital between late March and early May 2020.

'Time is vision' after a stroke
University of Rochester researchers studied stroke patients who experienced vision loss and found that the patients retained some visual abilities immediately after the stroke but these abilities diminished gradually and eventually disappeared permanently after approximately six months.

More stroke awareness, better eating habits may help reduce stroke risk for young adult African-Americans
Young African-Americans are experiencing higher rates of stroke because of health conditions such as high blood pressure, diabetes and obesity, yet their perception of their stroke risk is low.

How to help patients recover after a stroke
The existing approach to brain stimulation for rehabilitation after a stroke does not take into account the diversity of lesions and the individual characteristics of patients' brains.

Kids with headache after stroke might be at risk for another stroke
A new study has found a high incidence of headaches in pediatric stroke survivors and identified a possible association between post-stroke headache and stroke recurrence.

High stroke impact in low- and middle-income countries examined at 11th World Stroke Congress
Less wealthy countries struggle to meet greater need with far fewer resources.

Marijuana use might lead to higher risk of stroke, World Stroke Congress to be told
A five-year study of hospital statistics from the United States shows that the incidence of stroke has risen steadily among marijuana users even though the overall rate of stroke remained constant over the same period.

We need to talk about sexuality after stroke
Stroke survivors and their partners are not adequately supported to deal with changes to their relationships, self-identity, gender roles and intimacy following stroke, according to new research from the University of Sydney.

Standardized stroke protocol can ensure ELVO stroke patients are treated within 60 minutes
A new study shows that developing a standardized stroke protocol of having neurointerventional teams meet suspected emergent large vessel occlusion (ELVO) stroke patients upon their arrival at the hospital achieves a median door-to-recanalization time of less than 60 minutes.

Read More: Stroke News and Stroke Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to